Aberrant expression of COX-2 occurs in many types of
malignancies including colon and
lung cancers, and is implicated in development and progression of
cancer. The molecular mechanisms associated with aberrant expression of COX-2 in
lung cancer cells remain to be fully elucidated. In this study, we found that
non-small cell lung cancer (NSCLC) NCI-H520 and NCI-H460 cells constitutively expressed COX-2 and produced
prostaglandin E2 (
PGE2) as measured by Western blotting and
enzyme-linked
immunosorbent assay (ELISA), respectively. Reporter assays showed that transcriptional regulation of COX-2 was blunted when either the
NF-IL6 (
C/EBPbeta) or
nuclear factor-kappaB (
NF-kappaB) binding site in the COX-2 promoter was mutated, suggesting that
C/EBPbeta and
NF-kappaB transcription factors have an important role in aberrant expression of COX-2 in these
lung cancer cells. In addition, the eight herbal mixture
PC-SPES (Lot. 5431219) caused growth arrest and apoptosis of NCI-H520 and NCI-H460 cells in association with blockade of
NF-kappaB and down-regulation of
C/EBPbeta, resulting in down-regulation of COX-2 and
PGE2 in these cells. On the other hand,
PC-SPES up-regulated the level of
C/EBPbeta in these cells. Taken together,
C/EBPbeta and
NF-kappaB may be promising molecular targets for COX-2 inhibition in
lung cancer cells.
PC-SPES might be useful in the adjuvant setting for the treatment of individuals with resected NSCLC as well as other types of
cancer in which COX-2 is activated.